$5.76 0.00 (0.00%)

Alpha Teknova, Inc. Common Stock (TKNO)

Alpha Teknova, Inc. (TKNO) is a biotechnology company that develops and supplies essential reagents and materials for the healthcare and life sciences industries. Focused on providing high-quality products for diagnostics, pharmaceutical research, and other laboratory applications, Teknova supports scientific discovery and clinical testing through innovation and reliable supply chains.

🚫 Alpha Teknova, Inc. Common Stock does not pay dividends

Company News

Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies
GlobeNewswire Inc. • Clear® Verified • March 11, 2025

Teknova and Pluristyx are collaborating to produce and commercialize Pluristyx's PluriFreeze cryopreservation system, which is designed to simplify the scale-up process for companies working to bring allogeneic cell therapies to market.

Telegraph Hill Partners buys $15m of Alpha Teknova shares at $1.24 each - Investing.com
Investing.com • Investing.Com • July 17, 2024

Telegraph Hill Partners, a major shareholder in Alpha Teknova, Inc., has increased its stake in the company through a private placement, purchasing shares worth approximately $15 million at $1.24 per share. This transaction reflects a positive outlook from Telegraph Hill Partners on Alpha Teknova's future prospects.

After Plunging -24.59% in 4 Weeks, Here's Why the Trend Might Reverse for Alpha Teknova (TKNO)
Zacks Investment Research • Zacks Equity Research • June 24, 2024

Alpha Teknova (TKNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Why Gritstone bio Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Benzinga • Lisa Levin • September 28, 2023

Gainers Inpixon (NASDAQ: INPX) shares rose 44.6% to $0.2023 in pre-market trading after gaining around 10% on Wednesday. Gritstone bio, Inc. (NASDAQ: GRTS) shares rose 37% to $1.63 in pre-market trading after the company announced it was awarded a BARDA contract to conduct a Phase 2b comparative study evaluating a next-generation vaccine candida...